GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » Shiller PE Ratio

Renovaro (Renovaro) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Renovaro Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Renovaro Shiller PE Ratio Historical Data

The historical data trend for Renovaro's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Shiller PE Ratio Chart

Renovaro Annual Data
Trend Mar13 Dec14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Renovaro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Renovaro's Shiller PE Ratio

For the Biotechnology subindustry, Renovaro's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovaro's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovaro's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Renovaro's Shiller PE Ratio falls into.



Renovaro Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Renovaro's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Renovaro's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.07/129.4194*129.4194
=-0.070

Current CPI (Dec. 2023) = 129.4194.

Renovaro Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.085 99.695 -0.110
201406 -0.094 100.560 -0.121
201409 -0.056 100.428 -0.072
201412 -0.100 99.070 -0.131
201503 -0.130 99.621 -0.169
201506 -0.150 100.684 -0.193
201509 -0.040 100.392 -0.052
201512 -0.040 99.792 -0.052
201603 -0.020 100.470 -0.026
201606 -0.080 101.688 -0.102
201609 -0.080 101.861 -0.102
201612 -0.100 101.863 -0.127
201703 -0.030 102.862 -0.038
201706 -0.015 103.349 -0.019
201709 -0.020 104.136 -0.025
201712 -0.080 104.011 -0.100
201803 -0.120 105.290 -0.148
201806 -0.057 106.317 -0.069
201809 -0.010 106.507 -0.012
201812 -0.450 105.998 -0.549
201903 -0.070 107.251 -0.084
201906 0.040 108.070 0.048
201909 -0.090 108.329 -0.108
201912 -0.040 108.420 -0.048
202003 -0.030 108.902 -0.036
202006 -0.090 108.767 -0.107
202009 -0.050 109.815 -0.059
202012 -0.060 109.897 -0.071
202103 -0.090 111.754 -0.104
202106 -0.370 114.631 -0.418
202109 -0.200 115.734 -0.224
202112 -0.130 117.630 -0.143
202203 -0.120 121.301 -0.128
202206 -1.720 125.017 -1.781
202209 -0.140 125.227 -0.145
202212 -0.080 125.222 -0.083
202303 -0.080 127.348 -0.081
202306 -0.410 128.729 -0.412
202309 -0.140 129.860 -0.140
202312 -0.070 129.419 -0.070

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Renovaro  (NAS:RENB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Renovaro Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Renovaro's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovaro (Renovaro) Business Description

Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
Executives
Leni Boeren director 2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks director CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard 10 percent owner VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette officer: Executive Vice President 2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu 10 percent owner 2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev director, 10 percent owner FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler other: Former director see note below 330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol director 606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen director STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche officer: Chief Financial Officer 318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne director NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Anderson Wittekind William 10 percent owner 8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leire, Eric Jean Marie director, officer: CEO; President C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060